We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: azacitidine
MedXY News
EnglishTag

azacitidine

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE Trial
Hematology-Oncologyacute myeloid leukemiaazacitidine

Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE Trial

By MedXY|Sep 9, 2026

The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive

Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management
Hematology-OncologyruxolitinibPhase II Trial
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management

By MedXY|Sep 3, 2026

The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry
Hematology-Oncologyacute myeloid leukemiaazacitidine

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

By MedXY|Jul 20, 2026

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study
Hematology-Oncologyazacitidinemyelodysplastic syndrome

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY|Oct 14, 2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use a

ENHANCE-3 Trial: Evaluating Magrolimab Addition to Venetoclax and Azacitidine in Untreated AML Unfit for Intensive Chemotherapy
Hematology-Oncologyacute myeloid leukemiaazacitidine

ENHANCE-3 Trial: Evaluating Magrolimab Addition to Venetoclax and Azacitidine in Untreated AML Unfit for Intensive Chemotherapy

By MedXY|Oct 5, 2025

The ENHANCE-3 phase 3 trial assessed whether adding magrolimab to venetoclax and azacitidine improves outcomes in untreated AML patients unfit for intensive chemotherapy, finding no survival benefit and a higher rate of fatal adverse events

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
Clinical UpdatesAMLazacitidine

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

By MedXY|Oct 1, 2025

A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results
Clinical Updatesacute myeloid leukaemiaazacitidine

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY|Oct 1, 2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study
Clinical Updatesazacitidineivosidenib

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

By MedXY|Sep 30, 2025

The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities